Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

BACKGROUND: MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials. Immunogenicity of MYL-1501D and reference insulin glargine was examined in both studies. METHODS: INSTRIDE 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Bin, Sengupta, Nilanjan, Rao, Anita, Donnelly, Charles, Waichale, Vinit, Roy, Arnab Sinha, Ramaswamy, Shilpa, Pathak, Divya, Bowsher, Ronald R., Raiter, Yaron, Aubonnet, Patrick, Barve, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235862/
https://www.ncbi.nlm.nih.gov/pubmed/34174848
http://dx.doi.org/10.1186/s12902-021-00797-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235862/
https://www.ncbi.nlm.nih.gov/pubmed/34174848
http://dx.doi.org/10.1186/s12902-021-00797-4

Ejemplares similares